Alumis Inc (ALMS)

$20.39 +0.31 (1.54%)
Market Cap 2.55B
Revenue (ttm) 24.05M
Net Income (ttm) -243.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,011.77%
Debt to Equity Ratio 0.00
Volume 729,500
Avg Vol 1,249,440
Day's Range N/A - N/A
Shares Out 127.49M
Stochastic %K 14%
Beta -0.56
Analysts Strong Sell
Price Target $40.11

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibo...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
TheDragonsClaw
TheDragonsClaw Jun. 3 at 8:46 PM
$TORO $TDIC $SPHL $ALMS 5 fo t
0 · Reply
Poester
Poester Jun. 3 at 3:40 PM
$ALMS Am adding more to my position right now, as we've hit a double bottom in the high 19's.
0 · Reply
jledet
jledet Jun. 3 at 11:42 AM
$ALMS how long do you think before this starts the climb to $35-40?
1 · Reply
amessagefromtheodd
amessagefromtheodd May. 30 at 11:02 AM
$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿
1 · Reply
Sihtegroftnod
Sihtegroftnod May. 30 at 12:58 AM
$ALMS $CAPR $SLS $TERN This! Right here!!
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 30 at 12:48 AM
$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.
0 · Reply
IN0V8
IN0V8 May. 21 at 5:19 PM
$ALMS watch Aeluma. They pioneered the heterogeneous integration of compound semiconductors on mismatched substrates. This technology provides a viable path to manufacturing high-performance electronics and photonics with large-volume microelectronics manufacturing. Aeluma’s technology has the potential to overcome supply chain constraints and enable scaling and broad market adoption across AI infrastructure, consumer sensing, defense and aerospace, and quantum.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 20 at 1:49 PM
$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20
1 · Reply
laaarsas
laaarsas May. 20 at 8:50 AM
$ALMS Anyone has other view on LUMUS? My conclusion is that it really is a gamble and we don't have much evidence supporting that TYK2 works as a target in SLE. Does not mean it's likely not to work. Overall SLE trials have very large variation in placebo response, from that alone we could see an effect. But then it's just a gamble, not an investment.
0 · Reply
laaarsas
laaarsas May. 19 at 7:31 PM
$ALMS PEOTYK SLE-1 and 2 will report after LUMUS. Too bad. No chance to de-risk.
1 · Reply
Latest News on ALMS
Alumis price target raised to $40 from $38 at Chardan

2026-05-19T12:01:10.000Z - 16 days ago

Alumis price target raised to $40 from $38 at Chardan

Alumis Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 17 days ago

Alumis Proxy statement: Proxy filing

Alumis Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 17 days ago

Alumis Proxy statement: Proxy filing

Alumis price target raised to $39 from $38 at Morgan Stanley

2026-05-15T12:49:04.000Z - 20 days ago

Alumis price target raised to $39 from $38 at Morgan Stanley

Alumis price target raised to $51 from $49 at Wells Fargo

2026-05-15T11:13:04.000Z - 20 days ago

Alumis price target raised to $51 from $49 at Wells Fargo

Alumis Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 20 days ago

Alumis Slides: Corporate presentation

Alumis price target raised to $34 from $32 at Guggenheim

2026-05-15T10:58:47.000Z - 20 days ago

Alumis price target raised to $34 from $32 at Guggenheim

Alumis downgraded to Neutral from Buy at H.C. Wainwright

2026-05-15T10:10:10.000Z - 20 days ago

Alumis downgraded to Neutral from Buy at H.C. Wainwright

Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year

2026-05-14T21:23:34.000Z - 21 days ago

Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

May 14, 2026, 4:05 PM EDT - 21 days ago

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

Alumis Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 21 days ago

Alumis Earnings release: Q1 2026

Alumis Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 21 days ago

Alumis Quarterly report: Q1 2026

Alumis falls -16.1%

2026-03-30T16:08:52.000Z - 2 months ago

Alumis falls -16.1%

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

2026-03-30T15:50:16.000Z - 2 months ago

Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James

JNJ TAK

Alumis price target raised to $55 from $50 at Oppenheimer

2026-03-30T11:51:26.000Z - 2 months ago

Alumis price target raised to $55 from $50 at Oppenheimer

JNJ TAK

Alumis price target lowered to $25 from $40 at H.C. Wainwright

2026-03-30T10:15:07.000Z - 2 months ago

Alumis price target lowered to $25 from $40 at H.C. Wainwright

Alumis Transcript: Study update

Mar 29, 2026, 7:00 PM EDT - 2 months ago

Alumis Transcript: Study update

Alumis Press release: Study update

Mar 29, 2026, 7:00 PM EDT - 2 months ago

Alumis Press release: Study update

Alumis Slides: Study update

Mar 29, 2026, 7:00 PM EDT - 2 months ago

Alumis Slides: Study update

Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

2026-03-29T14:30:06.000Z - 2 months ago

Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Mar 28, 2026, 1:30 PM EDT - 2 months ago

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis price target raised to $38 from $33 at Morgan Stanley

2026-03-20T10:51:00.000Z - 2 months ago

Alumis price target raised to $38 from $33 at Morgan Stanley

Alumis files automatic mixed securities shelf

2026-03-19T21:05:19.000Z - 2 months ago

Alumis files automatic mixed securities shelf

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Mar 19, 2026, 4:05 PM EDT - 2 months ago

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Annual report: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 2 months ago

Alumis Annual report: Q4 2025

Alumis Earnings release: Q4 2025

Mar 19, 2026, 4:00 PM EDT - 2 months ago

Alumis Earnings release: Q4 2025

Alumis Slides: Corporate presentation

Mar 19, 2026, 7:00 AM EDT - 2 months ago

Alumis Slides: Corporate presentation

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 8:00 AM EDT - 2 months ago

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis initiated with a Strong Buy at Raymond James

2026-03-10T20:10:32.000Z - 3 months ago

Alumis initiated with a Strong Buy at Raymond James

Alumis Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:40 AM EDT - 3 months ago

Alumis Transcript: Leerink Global Healthcare Conference 2026

Alumis to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:05 AM EST - 3 months ago

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 3:20 PM EST - 3 months ago

Alumis Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Alumis initiated with a Buy at Stifel

2026-02-24T21:46:41.000Z - 3 months ago

Alumis initiated with a Buy at Stifel

Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 9:00 AM EST - 4 months ago

Alumis Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Alumis to Participate in Upcoming February Investor Conferences

Feb 5, 2026, 8:05 AM EST - 4 months ago

Alumis to Participate in Upcoming February Investor Conferences

Alumis rises 7.8%

2026-02-02T15:05:49.000Z - 4 months ago

Alumis rises 7.8%

Alumis initiated with a Buy at Chardan

2026-01-21T09:40:27.000Z - 4 months ago

Alumis initiated with a Buy at Chardan

Alumis rises 10.2%

2026-01-14T17:07:36.000Z - 5 months ago

Alumis rises 10.2%

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 9, 2026, 4:05 PM EST - 5 months ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Alumis price target raised to $40 from $20 at H.C. Wainwright

2026-01-09T11:16:29.000Z - 5 months ago

Alumis price target raised to $40 from $20 at H.C. Wainwright

Alumis 17.65M share Secondary priced at $17.00

2026-01-08T11:26:06.000Z - 5 months ago

Alumis 17.65M share Secondary priced at $17.00

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 10:52 PM EST - 5 months ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 5 months ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 5 months ago

Alumis Transcript: Study Result

Alumis Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 5 months ago

Alumis Press release: Study Result

Alumis Slides: Study Result

Jan 6, 2026, 8:00 AM EST - 5 months ago

Alumis Slides: Study Result

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 5 months ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 5 months ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 5 months ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 7 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 7 months ago

Alumis Quarterly report: Q3 2025

Alumis Earnings release: Q3 2025

Nov 13, 2025, 4:00 PM EST - 7 months ago

Alumis Earnings release: Q3 2025

Alumis Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 2:00 PM EST - 7 months ago

Alumis Transcript: Stifel 2025 Healthcare Conference

Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 1:30 PM EST - 7 months ago

Alumis Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 7 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 16, 2025, 12:30 PM EDT - 9 months ago

Alumis Transcript: Stifel Virtual Immunology and Inflammation Forum

Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 4:50 PM EDT - 9 months ago

Alumis Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 5, 2025, 9:30 AM EDT - 9 months ago

Alumis Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Alumis Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:45 AM EDT - 9 months ago

Alumis Transcript: Cantor Global Healthcare Conference 2025

Alumis Slides: Corporate Presentation

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Alumis Slides: Corporate Presentation

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 9 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 10 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Alumis Quarterly report: Q2 2025

Alumis Earnings release: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 10 months ago

Alumis Earnings release: Q2 2025

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 11 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 11 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis Registration statement: Registration Filing

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Alumis Registration statement: Registration Filing

Alumis Proxy statement: Proxy Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alumis Proxy statement: Proxy Filing

Alumis Proxy statement: Proxy Filing

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alumis Proxy statement: Proxy Filing

Alumis Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:10 PM EDT - 1 year ago

Alumis Transcript: Jefferies Global Healthcare Conference 2025

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 1 year ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 1 year ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 1 year ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Quarterly report: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Alumis Quarterly report: Q1 2025

Alumis Earnings release: Q1 2025

May 14, 2025, 12:00 AM EDT - 1 year ago

Alumis Earnings release: Q1 2025

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 1 year ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 1 year ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 1 year ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 1 year ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 1 year ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis Annual report: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Alumis Annual report: Q4 2024

Alumis Earnings release: Q4 2024

Mar 19, 2025, 4:00 PM EDT - 1 year ago

Alumis Earnings release: Q4 2024

Alumis Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 10:40 AM EDT - 1 year ago

Alumis Transcript: Leerink’s Global Healthcare Conference 2025

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 1 year ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 3:20 PM EST - 1 year ago

Alumis Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis Transcript: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Transcript: M&A Announcement

Alumis Press release: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Press release: M&A Announcement

Alumis Slides: M&A Announcement

Feb 6, 2025, 5:00 PM EST - 1 year ago

Alumis Slides: M&A Announcement

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Alumis Quarterly report: Q3 2024

Alumis Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Alumis Earnings release: Q3 2024

Alumis Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Nov 12, 2024, 2:00 PM EST - 1 year ago

Alumis Transcript: Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 10:55 AM EDT - 1 year ago

Alumis Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Quarterly report: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Alumis Quarterly report: Q2 2024

Alumis Earnings release: Q2 2024

Aug 13, 2024, 4:00 PM EDT - 1 year ago

Alumis Earnings release: Q2 2024

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Jun 28, 2024, 12:58 PM EDT - 2 years ago

Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Jun 28, 2024, 12:43 AM EDT - 2 years ago

Therapy developer Alumis prices U.S. IPO at about $902 mln valuation

Alumis Announces Pricing of Initial Public Offering

Jun 27, 2024, 11:57 PM EDT - 2 years ago

Alumis Announces Pricing of Initial Public Offering

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Jun 24, 2024, 8:27 AM EDT - 2 years ago

Therapy developer Alumis seeks up to $1 bln valuation in US IPO

Alumis Registration statement: Registration Filing

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Alumis Registration statement: Registration Filing

Alumis eyes $300 million in proceeds in IPO

Jun 24, 2024, 7:18 AM EDT - 2 years ago

Alumis eyes $300 million in proceeds in IPO

TheDragonsClaw
TheDragonsClaw Jun. 3 at 8:46 PM
$TORO $TDIC $SPHL $ALMS 5 fo t
0 · Reply
Poester
Poester Jun. 3 at 3:40 PM
$ALMS Am adding more to my position right now, as we've hit a double bottom in the high 19's.
0 · Reply
jledet
jledet Jun. 3 at 11:42 AM
$ALMS how long do you think before this starts the climb to $35-40?
1 · Reply
amessagefromtheodd
amessagefromtheodd May. 30 at 11:02 AM
$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿
1 · Reply
Sihtegroftnod
Sihtegroftnod May. 30 at 12:58 AM
$ALMS $CAPR $SLS $TERN This! Right here!!
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 30 at 12:48 AM
$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.
0 · Reply
IN0V8
IN0V8 May. 21 at 5:19 PM
$ALMS watch Aeluma. They pioneered the heterogeneous integration of compound semiconductors on mismatched substrates. This technology provides a viable path to manufacturing high-performance electronics and photonics with large-volume microelectronics manufacturing. Aeluma’s technology has the potential to overcome supply chain constraints and enable scaling and broad market adoption across AI infrastructure, consumer sensing, defense and aerospace, and quantum.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 20 at 1:49 PM
$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20
1 · Reply
laaarsas
laaarsas May. 20 at 8:50 AM
$ALMS Anyone has other view on LUMUS? My conclusion is that it really is a gamble and we don't have much evidence supporting that TYK2 works as a target in SLE. Does not mean it's likely not to work. Overall SLE trials have very large variation in placebo response, from that alone we could see an effect. But then it's just a gamble, not an investment.
0 · Reply
laaarsas
laaarsas May. 19 at 7:31 PM
$ALMS PEOTYK SLE-1 and 2 will report after LUMUS. Too bad. No chance to de-risk.
1 · Reply
laaarsas
laaarsas May. 19 at 7:11 PM
$ALMS I don't get it. What tells us that ESK-001 should work in SLE? From available knowledge, it does not seem clear to me.
0 · Reply
laaarsas
laaarsas May. 19 at 6:08 PM
$ALMS God fucking damnit. The case for LUMUS is not so clean really.
0 · Reply
laaarsas
laaarsas May. 19 at 3:02 PM
$ALMS Risk seems to be bigger compared to ONWARD. Unfortunately. Cannot go as big as one could have done, I think.
0 · Reply
laaarsas
laaarsas May. 19 at 2:58 PM
$ALMS Why did they chose to not have steroid tapering? I don't really get it. What are pros and cons? Seems like a risk to me.
0 · Reply
jledet
jledet May. 19 at 1:10 PM
$ALMS Bullish
0 · Reply
laaarsas
laaarsas May. 19 at 12:29 PM
$ALMS Steroid noise biggest risk for LUMUS. How will the company handle this?
0 · Reply
laaarsas
laaarsas May. 19 at 12:18 PM
$ALMS Surprised I did not know about LUMUS. Seems good. No apparent catch so far, just a few things I have to look into.
0 · Reply
laaarsas
laaarsas May. 19 at 11:22 AM
$ALMS So I already made some good money here on really clean ph2=>ph3 play for psoriasis. Is it time to make some more money on LUMUS? What do you guys think? Are you bullish?
1 · Reply
IN0V8
IN0V8 May. 18 at 2:54 PM
$ALMS Added ay $22
0 · Reply
Quantumup
Quantumup May. 15 at 11:28 AM
Guggenheim⬆️ $ALMS's PT to $34 and reiterated at Buy after the company's 1Q26 earnings release. $JNJ - $PTGX ORKA TAK BMY ABBV ARQT MLTX Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2055248200810836423?s=20
0 · Reply
TradeSun
TradeSun May. 4 at 10:35 AM
$ALT $ALMS $VERA $XBI Recent investments by Deep Track Capital
1 · Reply
droog_botski
droog_botski May. 1 at 7:36 PM
$ALMS What kind of joker buys (?) 252 May 15 1 dollar calls ?
1 · Reply